Atom Investors’s Rhythm Pharmaceuticals RYTM Stock Holding History

Atom Investors’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.16M	Buy	73,465 +16,465	+29%	+$1.49M	0.73%	5
2026 Q1	$4.96M	Buy	57,000 +34,071	+149%	+$3.31M	0.36%	79
2025 Q4	$2.45M	Buy	+22,929	New	+$2.43M	0.19%	166
2025 Q3	–	Sell	-14,866	Closed	-$939K	–	785
2025 Q2	$939K	Sell	14,866 -96	-0.6%	-$5.88K	0.08%	257
2025 Q1	$793K	Buy	14,962 +3,357	+29%	+$186K	0.1%	240
2024 Q4	$650K	Buy	+11,605	New	+$641K	0.08%	292
2024 Q3	–	Sell	-26,629	Closed	-$1.09M	–	587
2024 Q2	$1.09M	Sell	26,629 -14,647	-35%	-$585K	0.11%	235
2024 Q1	$1.79M	Buy	41,276 +16,345	+66%	+$715K	0.22%	157
2023 Q4	$1.15M	Buy	24,931 +5,545	+29%	+$175K	0.2%	169
2023 Q3	$444K	Buy	+19,386	New	+$434K	0.1%	252

Other funds holding RYTM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Atom Investors's RYTM Position: Q2 2026 in Review

Atom Investors increased its Rhythm Pharmaceuticals (RYTM) stake by 29% in Q2 2026, buying an estimated $1.49M and bringing the position to 73,465 shares worth $8.16M. The position accounts for 0.73% of the portfolio, ranked #5.

Atom Investors first reported a position in RYTM in Q3 2023 and has held it in 10 quarters since. 304 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

Atom Investors held 73,465 shares of Rhythm Pharmaceuticals worth $8.16M as of Q2 2026.
Atom Investors bought 16,465 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $1.49M.
Rhythm Pharmaceuticals made up 0.73% of Atom Investors's portfolio in Q2 2026, its #5 holding.
Atom Investors first reported a position in Rhythm Pharmaceuticals in Q3 2023 and has held it in 10 quarters since.
304 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Atom Investors's 13F filing for Q2 2026, filed 14 Aug 2026.